Lyra Therapeutics (LYRA) Stock Forecast, Price & News

Lyra Therapeutics (NASDAQ:LYRA) Frequently Asked Questions

Is Lyra Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Lyra Therapeutics stock.
View analyst ratings for Lyra Therapeutics or view top-rated stocks.

Are investors shorting Lyra Therapeutics?

Lyra Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 375,600 shares, an increase of 50.0% from the April 15th total of 250,400 shares. Based on an average daily trading volume, of 222,400 shares, the short-interest ratio is presently 1.7 days.
View Lyra Therapeutics' Short Interest.

When is Lyra Therapeutics' next earnings date?

Lyra Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Lyra Therapeutics.

How were Lyra Therapeutics' earnings last quarter?

Lyra Therapeutics, Inc. (NASDAQ:LYRA) released its quarterly earnings results on Wednesday, March, 9th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.23. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $1 million.
View Lyra Therapeutics' earnings history.

Who are Lyra Therapeutics' key executives?

Lyra Therapeutics' management team includes the following people:

• Dr. Maria Palasis Ph.D., CEO, Pres & Director (Age 56, Pay $848.19k)
• Mr. Jason Cavalier, CFO, Treasurer & Sec.
• Mr. R. Donald Elsey MBA, Advisor (Age 68, Pay $640.11k)
• Ms. Corinne Noyes, Sr. VP of Commercial Strategy & Market Devel. (Age 54, Pay $426.73k)
• Dr. Harlan W. Waksal M.D., Exec. Chairman (Age 69)
• Dr. Carmichael S. Roberts Jr., Ph.D., Co-Founder (Age 54)
• Mr. Ray Knox, VP of Operations
• Dr. Robert Richard Ph.D., Sr. VP of Technical Operations (Age 65)
• Ms. Vineeta Belanger Ph.D., Sr. VP of Clinical Affairs
• Ms. Pamela E. Nelson, Sr. VP of Regulatory Affairs (Age 52)

Who are some of Lyra Therapeutics' key competitors?

Some companies that are related to Lyra Therapeutics include Social Capital Suvretta Holdings Corp. I (DNAA), Invo Bioscience (IVOB), Tactile Systems Technology (TCMD), ClearPoint Neuro (CLPT), Accuray (ARAY), Assure (ARHH), Apollo Endosurgery (APEN), InfuSystem (INFU), InfuSystem (INFU), Co-Diagnostics (CODX), Meihua International Medical Technologies (MHUA), Beyond Air (XAIR), Quipt Home Medical (QIPT), Profound Medical (PROF) and DarioHealth (DRIO).
View all of LYRA's competitors.

What other stocks do shareholders of Lyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE).

When did Lyra Therapeutics IPO?

(LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager.

What is Lyra Therapeutics' stock symbol?

Lyra Therapeutics trades on the NASDAQ under the ticker symbol "LYRA."

Who are Lyra Therapeutics' major shareholders?

Lyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Clearline Capital LP (0.92%), Renaissance Technologies LLC (0.13%) and JPMorgan Chase & Co. (0.06%). Company insiders that own Lyra Therapeutics stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta and Nbvm Gp, Llc.
View institutional ownership trends for Lyra Therapeutics.

Which institutional investors are selling Lyra Therapeutics stock?

LYRA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Lyra Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Lyra Therapeutics stock?

LYRA stock was purchased by a variety of institutional investors in the last quarter, including Clearline Capital LP, and JPMorgan Chase & Co.. Company insiders that have bought Lyra Therapeutics stock in the last two years include C Ann Merrifield, Edward T Anderson, Harlan Waksal, and Nbvm Gp, Llc.
View insider buying and selling activity for Lyra Therapeutics or or view top insider-buying stocks.

How do I buy shares of Lyra Therapeutics?

Shares of LYRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyra Therapeutics' stock price today?

One share of LYRA stock can currently be purchased for approximately $5.07.

How much money does Lyra Therapeutics make?

Lyra Therapeutics has a market capitalization of $65.96 million and generates $280 thousand in revenue each year. The company earns $-43.51 million in net income (profit) each year or ($3.29) on an earnings per share basis.

How many employees does Lyra Therapeutics have?

Lyra Therapeutics employs 53 workers across the globe.

What is Lyra Therapeutics' official website?

The official website for Lyra Therapeutics is www.lyratherapeutics.com.

How can I contact Lyra Therapeutics?

Lyra Therapeutics' mailing address is 480 ARSENAL STREET, WATERTOWN MA, 02472. The company can be reached via phone at 617-373-4600 or via email at [email protected].